Drug
Elamipretide clinical trials
Also written MTP-131 and Bendavia.
- studies test it
- 27
- open now
- 1
- in phase 3
- 4
- first study started
- 2010
Keep track of what changes. Save the elamipretide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2016 (7)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 5 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 7 |
| 2017 | 2 |
| 2019 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 14
- Phase 3
- 4
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 1
Stealth BioTherapeutics Inc. (26) · Children's Hospital of Philadelphia (1)
Studies
Open first, then newest update. How each study uses elamipretide is read from its arms, and is right about nine times in ten.
Testing it · 27
- Clinical Trial in Patients With Barth Syndrome- 4TAZPowerRecruitingPhase 4Stealth BioTherapeutics Inc.NCT07531251Written as Elamipretide
- ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)Active, not recruitingPhase 3Stealth BioTherapeutics Inc.NCT06373731Written as Elamipretide
- FRDA Investigator Initiated Study (IIS) With ElamipretideCompletedPhase 1/2Children's Hospital of PhiladelphiaNCT05168774Written as Elamipretide
- Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)CompletedPhase 3Stealth BioTherapeutics Inc.NCT05162768Written as Elamipretide
- ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GACompletedPhase 2Stealth BioTherapeutics Inc.NCT03891875Written as Subcutaneous elamipretide through the elamipretide delivery system
- A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth SyndromeCompletedPhase 2/3Stealth BioTherapeutics Inc.NCT03098797Written as Elamipretide
- A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label ExtensionTerminatedPhase 3Stealth BioTherapeutics Inc.NCT03323749Written as elamipretide
- Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)TerminatedPhase 2Stealth BioTherapeutics Inc.NCT02976038Written as elamipretide
- A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic NeuropathyCompletedPhase 2Stealth BioTherapeutics Inc.NCT02693119Written as elamipretide (MTP-131) 1% topical ophthalmic solution
- An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular DegenerationCompletedPhase 1Stealth BioTherapeutics Inc.NCT02848313Written as Elamipretide
- Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal ArteryTerminatedPhase 1/2Stealth BioTherapeutics Inc.NCT01755858Written as Bendavia
- A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart FailureCompletedPhase 2Stealth BioTherapeutics Inc.NCT02914665Written as elamipretide
- Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER StudyCompletedPhase 2Stealth BioTherapeutics Inc.NCT02805790Written as Elamipretide
- A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in ElderlyCompletedPhase 2Stealth BioTherapeutics Inc.NCT02245620Written as Elamipretide
- Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary EventsCompletedPhase 2Stealth BioTherapeutics Inc.NCT01572909Written as Bendavia (MTP-131)
- Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection FractionCompletedPhase 2Stealth BioTherapeutics Inc.NCT02788747Written as 4 mg elamipretide
- Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial MyopathyCompletedPhase 1/2Stealth BioTherapeutics Inc.NCT02367014Written as elamipretide (low dose)
- A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection FractionCompletedPhase 2Stealth BioTherapeutics Inc.NCT02814097Written as elamipretide
- A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal FunctionCompletedPhase 1Stealth BioTherapeutics Inc.NCT02436447Written as MTP-131
- A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular DegenerationCompletedPhase 1/2Stealth BioTherapeutics Inc.NCT02314299Written as MTP-131
Codes
What other systems call elamipretide · ClinicalTrials.gg INT004846
- MeSH (NLM) C506540elamipretideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 87GWG91S09ELAMIPRETIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q27269822elamipretideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171874ElamipretideOne source FDA
- DrugBank DB11981One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C506540 | elamipretide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 87GWG91S09 | ELAMIPRETIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27269822 | elamipretide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171874 | Elamipretide | One source FDA |
| DrugBank | DB11981 | — | One source Wikidata |
Also registered as elamipretide hydrochloride (UNII E40WZ3BK2D).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.